Catalent’s Optiform Platform Now Available

Catalent Pharma Solutions has released its Optiform compound optimization platform, a solid-state and highly-automated analysis platform for salt, crystal-form, and co-crystal screening.

The technology, developed during the past ten years within GlaxoSmithKline, is designed to create faster and more material-efficient development workflows. The Optiform platform has been applied to more than 500 compounds, spanning from early stage lead compounds through launched products. GSK entered into an agreement with Catalent to use the Optiform platform to support its internal screening activities. The Optiform compound optimization platform and team will join Catalent’s Development and Clinical Services team based in Research Triangle Park, NC.

“My team and I are very excited that other companies now have access to these industry-proven technologies and workflows. I am confident that Catalent customers will value their effectiveness as much as GSK has. The pairing of leading-edge technology with a scientific team that has been embedded in hundreds of project teams to successfully address solid-state problems spanning lead-identification to commercial launch is unparalleled,” said David Igo, Ph.D., director, Optiform.

“We are pleased to add this world-class compound screening technology and the dedicated team of scientific experts led by Dr. Igo.It is an important new, early development offering for our customers. We believe that the Optiform technology provides yet another means for Catalent to help our customers reduce development time and build a more robust product,” said Kent Payne, Ph.D., vice president and general manager, Development Services at Catalent.